DMRA · Damora Therapeutics, Inc. · Analyst Estimates
$28.10
+1.26 (+4.69%)
At close · Sep 11
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.73B
Shares
61.74M
Analyst Estimates
Compare analyst forecasts for Damora Therapeutics, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Only independently verified consensus published through the company's investor-relations sources is available.
Consensus not yet available
Only independently verified consensus published through the company's investor-relations sources is available.
Key facts
CIK
1800315
CUSIP
G2646Y104
13F (30d)
52 filings
52 filers
Visit website
Investor relations